Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Anticoagulation Reversal and Risk of Thromboembolic Events Among Heart Transplant Recipients Bridged with Durable Mechanical Circulatory Support Devices

Moretz, Jeremy*; Lindenfeld, Joann*; Shah, Ashish; Wigger, Mark*; Schlendorf, Kelly*; Keebler, Mary*; Danter, Matthew; Brown Sacks, Suzanne*; Ooi, Henry*; Brinkley, Marshall*; Hanna, Peter*; Zalawadiya, Sandip*

doi: 10.1097/MAT.0000000000000866
Adult Circulatory Support
Buy
SDC

Anticoagulation reversal agents (ARAs) can minimize bleeding complications associated with mechanical circulatory support devices (MCSDs) explantation at the time of heart transplantation (HT); data on thromboembolic (TE) risk associated with ARAs are limited in this patient population. In this single-center study, we retrospectively analyzed 118 consecutive adults who were supported with durable MCSDs and underwent HT between May 2013 and October 2016. Patients were categorized based on intraoperative use of ARAs (recombinant factor VIIa [n=23], 4-factor prothrombin complex concentrate [n=48], or factor IX complex [n=2]) at the time of HT; these agents were used at discretion of implanting surgeons for bleeding control. The primary outcome of interest was presence of venous or systemic TE events within 3 months of HT. Multivariable logistic regression analyses were used to assess association between TE events and use of ARAs. A total of 71 (60%) patients received ARAs, and a total of 32 patients (27.1%) had TE events (25 venous [median time to diagnosis: 11.5 days; interquartile range {IQR}: 9–31 days], and 10 systemic [median time to diagnosis: 5.5 days; IQR: 4–8 days]); 26 (81.2%) of those with TE events had ARAs used at the time of HT. Multivariable analysis identified use of ARAs as an independent predictor of TE events (multivariable odds ratio: 3.06; 95% CI: 1.09–8.58; p = 0.034). Unplanned intraoperative use of ARAs to control bleeding was associated with a significantly higher risk of TE events among HT recipients bridged with durable MCSD. Future studies are required to further assess safety of these agents and their impact on patient outcomes.

From the *Division of Heart Failure and Transplantation

Division of Cardiac Surgery, Vanderbilt University Medical Center, Nashville, Tennessee.

Twitter: @Twitter

Submitted for consideration January 2018; accepted for publication in revised form July 2018.

Disclosure: The authors have no conflicts of interest to report.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML and PDF versions of this article on the journal’s Web site (www.asaiojournal.com)

Correspondence: Sandip Zalawadiya, 1215 21st Ave S Room 5209, Nashville, TN 37232. Email: sandip.zalawadiya@gmail.com.

Copyright © 2019 by the American Society for Artificial Internal Organs